Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials

No abstract is available for this paper.

• Publication year

  2007

• Venue

  British Journal of Psychiatry

• Publication date

  2007-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1192/bjp.bp.106.028555PMID 17401033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Demand Characteristics and the Concept of Quasi-Controls1

  2009cited by this paper
• The Naturalistic Course of Unipolar Major Depression in the Absence of Somatic Therapy

  2006cited by this paper
• Is there a delay in the antidepressant effect? A meta-analysis.

  2005cited by this paper
• Cianopramine and amitriptyline in the treatment of depressed patients — a placebo-controlled study

  2004cited by this paper
• Integrating outcomes research into clinical practice.

  2002cited by this paper
• A reevaluation of the exclusion criteria used in antidepressant efficacy trials.

  2002cited by this paper
• Are placebo controls necessary to test new antidepressants and anxiolytics?

  2002cited by this paper
• Placebo response in studies of major depression: variable, substantial, and growing.

  2002cited by this paper
• Clinical efficacy of reboxetine in major depression.

  2000cited by this paper
• Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.

  2000cited by this paper
• Short-term spontaneous improvement rates in depressed outpatients.

  2000cited by this paper
• Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.

  1999cited by this paper
• How expectancies shape experience.

  1999cited by this paper
• How should efficacy be evaluated in randomized clinical trials of treatments for depression?

  1999cited by this paper
• A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.

  1999cited by this paper
• Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication

  1998cited by this paper
• A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.

  1998cited by this paper
• The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.

  1998cited by this paper
• Efficacy and Tolerability of Once-Daily Venlafaxine Extended Release (XR) in Outpatients With Major Depression

  1997cited by this paper
• Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.

  1997cited by this paper
• Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

  1997cited by this paper
• Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients.

  1996cited by this paper
• A double-blind placebo-controlled study of Org 3770 in depressed outpatients.

  1995cited by this paper
• A randomised, double‐blind, placebo‐controlled, 5‐weeks' study of org 3770 (mirtazapine) in major depression

  1995cited by this paper
• A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.

  1995cited by this paper
• A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression.

  1995cited by this paper
• Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo

  1995cited by this paper
• Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo.

  1995cited by this paper
• A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression.

  1995cited by this paper
• A double‐blind, placebo‐controlled study comparing mianserin and amitriptyline in moderately depressed outpatients

  1994cited by this paper
• Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.

  1994cited by this paper
• A comparison of venlafaxine, trazodone, and placebo in major depression.

  1994cited by this paper
• Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. Prothiaden Collaborative Study Group.

  1994cited by this paper
• A double-blind comparison of nefazodone, imipramine, and placebo in major depression.

  1994cited by this paper
• Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.

  1993cited by this paper
• Serotonin activity in psychotic (delusional) major depression.

  1992cited by this paper
• A meta-analysis of antidepressant outcome under "blinder" conditions.

  1992cited by this paper
• Basic advances in serotonin pharmacology.

  1992cited by this paper
• Paroxetine in major depression: a double-blind trial with imipramine and placebo.

  1992cited by this paper
• A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.

  1992cited by this paper
• A double-blind, placebo-controlled study of paroxetine in depressed outpatients.

  1992cited by this paper
• A placebo-controlled trial of paroxetine in the treatment of major depression.

  1992cited by this paper
• Paroxetine versus placebo: a double-blind comparison in depressed patients.

  1992cited by this paper
• A double-blind comparison of paroxetine, imipramine, and placebo in major depression.

  1992cited by this paper
• The efficacy and safety of paroxetine compared with placebo in outpatients with major depression.

  1992cited by this paper
• Adinazolam, Diazepam, Imipramine, and Placebo in Major Depressive Disorder: A Controlled Study*

  1991cited by this paper
• Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder.

  1990cited by this paper
• Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.

  1990cited by this paper
• A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients.

  1990cited by this paper
• Clovoxamine in the treatment of depressed outpatients: a double-blind, parallel-group comparison against amitriptyline and placebo.

  1990cited by this paper
• A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder.

  1989cited by this paper
• Paroxetine in the treatment of depression: a comparison with imipramine and placebo

  1989cited by this paper
• A Double-blind Comparative Trial of Moclobemide v. Imipramine and Placebo in Major Depressive Episodes

  1989cited by this paper
• Fluoxetine, a Selective Serotonin Uptake Inhibitor, for the Treatment of Outpatients with Major Depression

  1988cited by this paper
• Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients.

  1986cited by this paper
• A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression.

  1986cited by this paper
• A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.

  1985cited by this paper
• Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression.

  1985cited by this paper
• Response expectancy as a determinant of experience and behavior.

  1985cited by this paper
• A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.

  1985cited by this paper
• A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder.

  1983cited by this paper
• Comparison of alprazolam, imipramine, and placebo in the treatment of depression.

  1983cited by this paper
• A double‐blind, controlled evaluation of zimeldine, imipramine and placebo in patients with primary affective disorders

  1983cited by this paper
• An Investigation of Drug Expectancy as a Function of Capsule Color and Size and Preparation Form

  1982cited by this paper
• Classification of Placebo Drugs: Effect of Color

  1979cited by this paper
• Research diagnostic criteria: rationale and reliability.

  1978cited by this paper
• Artifact in behavioral research

  1969cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Minimizing placebo responses in clinical trials.

  2025cites this paper
• Measurement-Based Care to Enhance Antidepressant Treatment Outcomes in Major Depressive Disorder

  2025cites this paper
• Die Geschichte des medizinischen Modells der Depression – mit (fast) all ihren Vor- und Nachteilen

  2025cites this paper
• Open-Label Placebos for Antidepressant Discontinuation Symptoms: A Series of N-of-1 Trials

  2025cites this paper
• Phase-Based Care in Community Mental Health: A Cost-Effective Innovation Using Algorithms, Rating Scales and Treatment Teams for Depression Management

  2024cites this paper
• Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment‐resistant depression: A double‐blind, randomized, placebo‐controlled trial

  2024cites this paper
• Long-Term Effects of Internet-Based Cognitive Behavioral Therapy on Depression Prevention Among University Students: Randomized Controlled Factorial Trial

  2024cites this paper
• Esketamine Nasal Spray versus Quetiapine for Resistant Depression.

  2024cites this paper
• Treatment expectations and clinical outcomes following repetitive transcranial magnetic stimulation for treatment-resistant depression.

  2024cites this paper
• The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.

  2024cites this paper
• Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study

  2023cites this paper
• Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.

  2023cites this paper
• Méthodologie des essais thérapeutiques

  2023cites this paper
• Predictors of spontaneous remission and recovery among women with untreated perinatal depression in India and Pakistan

  2023cites this paper
• Zuranolone for the Treatment of Postpartum Depression.

  2023cites this paper
• Predictors of spontaneous remission and recovery among women with untreated 1 perinatal depression in India and Pakistan

  2023cites this paper
• Effects of sham acupuncture for chronic musculoskeletal pain syndrome: A systematic review and network meta-analysis of randomized controlled trials

  2023cites this paper
• Placebo Effect in Randomized Trials of Major Depressive Disorder With Psychotic Features

  2022cites this paper
• Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression.

  2021cites this paper
• Neuropsychopharmacotherapy: Aspects of Placebo Effects

  2021cites this paper
• Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials.

  2021cites this paper
• Differential Placebo Responses for Pharmacotherapy and Neurostimulation in Late-Life Depression.

  2021cites this paper
• Effects Of Exogenous Melatonin On Sleep And Circadian Rhythms In Women With Premenstrual Dysphoric Disorder.

  2021cites this paper
• Validation of a novel online depression symptom severity rating scale: the R8 Depression

  2021cites this paper
• Blinding and expectancy confounds in psychedelic randomized controlled trials

  2021cites this paper
• Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

  2021cites this paper
• Subjective cognition and mood in persistent chemotherapy-related cognitive impairment

  2021cites this paper
• Response to SSRI intervention and amygdala activity during self-referential processing in major depressive disorder

  2020cites this paper
• Impact of Clinical Outcome Measures on Placebo Response Rates in Clinical Trials for Chronic Constipation: A Systematic Review and Meta-analysis

  2020cites this paper
• John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials

  2020cites this paper
• Drugs to Treat Depression.

  2020cites this paper
• Engaging in Late-Life Mental Health Research: a Narrative Review of Challenges to Participation

  2020cites this paper
• Approval of esketamine for treatment-resistant depression.

  2020cites this paper
• The issue of indiscriminative efficacy trials and placebo effects in paediatric psychopharmacology

  2020cites this paper
• Not Just Nonspecific Factors: The Roles of Alliance and Expectancy in Treatment, and Their Neurobiological Underpinnings

  2019cites this paper
• Neurobiological Models of Psychotherapy: How Psychotherapy Changes the Brain

  2019influential citation
• Socioeconomic determinants affecting the access and utilization of depression care services in immigrants: A population-based study

  2019cites this paper
• On the Effects of Serotonin Reuptake Inhibitors in Major Depression

  2019cites this paper
• Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study

  2019cites this paper
• Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission

  2019influential citation
• Efficacy of the Home-Based Mental Health Evaluation (HOME) Program for Engaging Patients in Care After Hospitalization.

  2019cites this paper
• Impact of demographic factors on the antidepressant effect: A patient-level data analysis from depression trials submitted to the Pharmaceuticals and Medical Devices Agency in Japan.

  2018cites this paper
• Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial

  2018cites this paper
• Selbstheilungskräfte und der Placebo-Effekt

  2018cites this paper
• Addressing High Placebo Response in Neuroscience Clinical Trials

  2018cites this paper
• Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial

  2018cites this paper
• Factors associated with placebo response in depression trials: A systematic review of published meta-analyses (1990–2017)

  2018cites this paper
• Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

  2018cites this paper
• The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes.

  2017cites this paper
• Participant Preferences for Pharmacologic Chronic Pain Treatment Trial Characteristics: An ACTTION Adaptive Choice-Based Conjoint Study.

  2016cites this paper
• Are antidepressants and psychotherapy equally effective in treating depression? A critical commentary

  2016influential citation
• Improving Community Mental Health Services: The Need for a Paradigm Shif.

  2016cites this paper
• Internet-delivered acceptance-based behaviour therapy for generalized anxiety disorder: A randomized controlled trial.

  2016cites this paper
• The Need for Quality Improvement in Behavioral Health

  2016cites this paper
• Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis

  2016cites this paper
• Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered

  2016cites this paper
• From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings

  2015cites this paper
• Decision-making stress and satisfaction : a cognitive-affective model

  2015cites this paper
• INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS

  2015cites this paper
• Mental illness : an integrated model of help seeking

  2015cites this paper
• The combination of psychotherapy and pharmacotherapy in the treatment of adult depression: A comprehensive meta-analysis

  2015cites this paper
• Increasing placebo responses over time in U.S. clinical trials of neuropathic pain

  2015cites this paper
• Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

  2015cites this paper
• Understanding the Antidepressant Debate in the Treatment of Major Depressive Disorder.

  2015cites this paper
• Identification of Real and Artifactual Moderators of Effect Size in Meta-Analysis

  2015cites this paper
• Predictive Factors Associated With Success and Failure for Calmare (Scrambler) Therapy: A Multicenter Analysis

  2015cites this paper
• Therapeutic Alliance in Antidepressant Treatment: Cause or Effect of Symptomatic Levels?

  2015cites this paper
• An Investigation into the Neurobiology of Treatment Response in patients with Major Depression: The Placebo Effect.

  2015cites this paper
• Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).

  2015cites this paper
• Hippocampal Plasticity and Response to Antidepressant Treatment with SSRIs : a longitudinal study

  2015cites this paper
• Relationship of Number of Clinic Visits to Response during Placebo-Controlled Antidepressant Trials in Late Life Depression

  2015cites this paper
• Treatment Approaches for Dentin Hypersensitivity

  2014cites this paper
• Epidural Steroid Injections, Conservative Treatment, or Combination Treatment for Cervical Radicular Pain: A Multicenter, Randomized, Comparative-effectiveness Study

  2014cites this paper
• Title Role of pill-taking , expectation and therapeutic alliance in the placebo response in clinical trials for major depression Permalink

  2014cites this paper
• Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

  2014cites this paper
• A Double-Blind, Placebo-Controlled Study of Selegiline Transdermal System in Depressed Adolescents

  2014cites this paper
• Effect of variability in the 7‐day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: An ACTTION study

  2014cites this paper
• Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

  2014cites this paper
• Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression.

  2014cites this paper
• Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology

  2014influential citation
• Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome.

  2014cites this paper
• Examining relations between alpha power as well as anterior cingulate cortex-localized theta activity and response to single or dual antidepressant pharmacotherapies

  2014cites this paper
• A systematic approach to pharmacotherapy for geriatric major depression.

  2014cites this paper
• Letter to the Editor: Minimal clinical contact may contribute to Internet cognitive behavioural therapy (iCBT) efficacy relative to wait-list control condition

  2014cites this paper
• Conduite à tenir devant un épisode dépressif caractérisé chez l'adulte en médecine générale

  2014cites this paper
• Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.

  2013cites this paper
• Routledge Handbook of Physical Activity and Mental Health

  2013influential citation
• A call to arms: the credibility gap in interventional pain medicine and recommendations for future research.

  2013cites this paper
• Improving study design for antidepressant effectiveness assessment

  2013cites this paper
• Course, risk factors, and prognostic factors in elderly primary care patients with mild depression: A two-year observational study

  2013cites this paper
• Response prediction to antidepressants using scalp and source-localized loudness dependence of auditory evoked potential (LDAEP) slopes.

  2013cites this paper
• Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis

  2013cites this paper
• Vagus nerve stimulation for chronic major depressive disorder: 12-month outcomes in highly treatment-refractory patients.

  2013cites this paper
• A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

  2013cites this paper
• Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D.

  2013cites this paper
• Neuronal network plasticity and recovery from depression.

  2013cites this paper
• Depression in Primary Care: Current and Future Challenges

  2013cites this paper
• A model of placebo response in antidepressant clinical trials.

  2013cites this paper
• Is placebo useful in the treatment of major depression in clinical practice?

  2013cites this paper
• Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations

  2012cites this paper